West Pharmaceutical Services (WST) free cash flow

Free cash flow · fiscal 2025
$468.90M

West Pharmaceutical Services (WST) generated free cash flow of $468.90M in fiscal 2025 (the year ended December 31, 2025). That is 69.6% higher than the $276.40M of fiscal 2024. Figures as of 18 Nov 2026, 11:48 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$468.90M
Change on fiscal 2024
+69.6%
Growth, 5 years
+9.5% a year
Growth, 10 years
+19.2% a year
Highest on record
$468.90Mfiscal 2025
Lowest on record
-$3.60Mfiscal 2008
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

West Pharmaceutical Services free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow grew at a compound 9.5% a year; over ten years the rate was 19.2% a year. Across the 18 fiscal years on record (2008–2025), the highest was $468.90M in fiscal 2025 and the lowest -$3.60M in fiscal 2008.

History · 18 fiscal years

Free cash flow by fiscal year

West Pharmaceutical Services free cash flow, year by year

West Pharmaceutical Services (WST) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$468.90M 69.6% up
2024$276.40M 33.3% down
2023$414.50M 5.7% down
2022$439.40M 32.9% up
2021$330.60M 10.9% up
2020$298.10M 23.8% up
2019$240.80M 30.9% up
2018$183.90M 38.8% up
2017$132.50M 169.3% up
2016$49.20M 39.1% down
2015$80.80M 13.8% up
2014$71.00M 3.5% up
2013$68.60M 22.3% up
2012$56.10M 58.9% up
2011$35.30M 47.5% down
2010$67.20M 104.9% up
2009$32.80M—
2008-$3.60M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of West Pharmaceutical Services and comparable companies
CompanyFree cash flowFiscal year
Labcorp Holdings LH$1.21B2025
DexCom DXCM$1.08B2025
Koninklijke Philips PHG€504.00M2025
West Pharmaceutical Services WST$468.90M2025
Quest Diagnostics DGX$1.36B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on WST

West Pharmaceutical Services, figure by figure

West Pharmaceutical Services (WST) overview: price, valuation and scorecardAll health care companies by market value

West Pharmaceutical Services free cash flow: questions and answers

What is West Pharmaceutical Services's free cash flow?

West Pharmaceutical Services (WST) generated free cash flow of $468.90M in fiscal 2025 (the year ended December 31, 2025). That is 69.6% higher than the $276.40M of fiscal 2024.

What is the growth rate of West Pharmaceutical Services's free cash flow?

Over the five fiscal years to 2025 free cash flow grew at a compound 9.5% a year; over ten years the rate was 19.2% a year.

What are the highest and lowest free cash flow figures on record for West Pharmaceutical Services?

Across the 18 fiscal years on record (2008–2025), the highest was $468.90M in fiscal 2025 and the lowest -$3.60M in fiscal 2008.

How is West Pharmaceutical Services's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For West Pharmaceutical Services it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “West Pharmaceutical Services (WST) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/WST/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.